140 related articles for article (PubMed ID: 37625088)
1. A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal women.
Thurman A; Hull ML; Stuckey B; Hatheway J; Zack N; Mauck C; Friend D
Menopause; 2023 Sep; 30(9):940-946. PubMed ID: 37625088
[TBL] [Abstract][Full Text] [Related]
2. A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal women.
Thurman A; Hull ML; Stuckey B; Hatheway J; Zack N; Mauck C; Friend D
Menopause; 2023 Aug; 30(8):817-823. PubMed ID: 37339390
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 28-day estradiol and progesterone vaginal rings in a phase 1 clinical pharmacokinetic study.
Hull L; Stuckey BGA; Hartman K; Zack N; Friend DR
Menopause; 2023 Apr; 30(4):427-436. PubMed ID: 36727806
[TBL] [Abstract][Full Text] [Related]
4. Safety and acceptability of intravaginal rings releasing estradiol and progesterone.
Hull ML; Stuckey B; Hartman K; Zack N; Thurman A; Friend DR
Climacteric; 2023 Oct; 26(5):465-471. PubMed ID: 37054722
[TBL] [Abstract][Full Text] [Related]
5. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
6. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
[TBL] [Abstract][Full Text] [Related]
7. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
[TBL] [Abstract][Full Text] [Related]
8. Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial.
Diem SJ; Guthrie KA; Mitchell CM; Reed SD; Larson JC; Ensrud KE; LaCroix AZ
Menopause; 2018 Oct; 25(10):1086-1093. PubMed ID: 29738424
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert.
Mirkin S; Simon JA; Liu JH; Archer DF; Castro PD; Graham S; Bernick B; Komm B
Menopause; 2021 May; 28(9):998-1003. PubMed ID: 34054104
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial.
Black DR; Minkin MJ; Graham S; Bernick B; Mirkin S
Menopause; 2020 Sep; 28(1):32-39. PubMed ID: 32932401
[TBL] [Abstract][Full Text] [Related]
11. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause.
Archer DF; Bernick BA; Mirkin S
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):729-739. PubMed ID: 31282768
[No Abstract] [Full Text] [Related]
12. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
Constantine GD; Simon JA; Kaunitz AM; Pickar JH; Revicki DA; Graham S; Bernick B; Mirkin S
Menopause; 2020 Nov; 27(11):1236-1241. PubMed ID: 33110039
[TBL] [Abstract][Full Text] [Related]
13. Bioidentical Oral 17β-Estradiol and Progesterone for the Treatment of Moderate to Severe Vasomotor Symptoms of Menopause.
Woodis CB; Ghassemi E; McLendon AN
Ann Pharmacother; 2021 Sep; 55(9):1153-1158. PubMed ID: 33345556
[TBL] [Abstract][Full Text] [Related]
14. Effect of menopausal hormone therapy on arterial wall echomorphology: Results from the Early versus Late Intervention Trial with Estradiol (ELITE).
Karim R; Xu W; Kono N; Sriprasert I; Li Y; Yan M; Stanczyk FZ; Shoupe D; Mack WJ; Hodis HN
Maturitas; 2022 Aug; 162():15-22. PubMed ID: 35474254
[TBL] [Abstract][Full Text] [Related]
15. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
Lobo RA; Liu J; Stanczyk FZ; Constantine GD; Pickar JH; Shadiack AM; Bernick B; Mirkin S
Menopause; 2019 Jul; 26(7):720-727. PubMed ID: 30694918
[TBL] [Abstract][Full Text] [Related]
16. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial.
Caan B; LaCroix AZ; Joffe H; Guthrie KA; Larson JC; Carpenter JS; Cohen LS; Freeman EW; Manson JE; Newton K; Reed S; Rexrode K; Shifren J; Sternfeld B; Ensrud K
Menopause; 2015 Jun; 22(6):607-15. PubMed ID: 25405571
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms.
Lobo RA; Kaunitz AM; Santoro N; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Dec; 22(6):610-616. PubMed ID: 31364889
[No Abstract] [Full Text] [Related]
19. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
[TBL] [Abstract][Full Text] [Related]
20. A pilot study: estradiol/progesterone effect on cervico-vaginal cytokines in premenopause and postmenopause.
Sriprasert I; Pakrashi T; Shah A; Jacot T; Bernick B; Mirkin S; Archer DF
Climacteric; 2020 Jun; 23(3):306-310. PubMed ID: 32107942
[No Abstract] [Full Text] [Related]
[Next] [New Search]
